TY - JOUR
T1 - Fosinopril Prevents the Development of Tactile Allodynia in a Streptozotocin-Induced Diabetic Rat Model
AU - Araiza-Saldaña, Claudia Ivonne
AU - Pedraza-Priego, Erick Fabián
AU - Torres-Lõpez, Jorge Elías
AU - Rocha-González, Héctor Isaac
AU - Castañeda-Corral, Gabriela
AU - Hong-Chong, Enrique
AU - Granados-Soto, Vinicio
N1 - Publisher Copyright:
© 2015 Wiley Periodicals, Inc.
PY - 2015/12
Y1 - 2015/12
N2 - Preclinical Research The aim of this study was to evaluate fosinopril-induced changes in hemodynamic parameters and tactile allodynia in a rat model of diabetes. Diabetes was induced by streptozotocin (STZ; 50 mg/kg, i.p.) in male Wistar rats. STZ produced hyperglycemia, weight loss, polydipsia, polyphagia, and polyuria as well as long-term arterial hypotension, bradycardia, and tactile allodynia at 10-12 weeks. Daily administration of the angiotensin converting enzyme inhibitor, fosinopril (25 mg/kg, p.o., for 11 weeks) partially reduced the loss of body weight, decreased hyperglycemia, and systolic blood pressure in diabetic rats. Likewise, systemic administration of fosinopril prevented the development and maintenance of tactile allodynia in STZ-induced diabetic rats. These data suggest that fosinopril may have a role in the pharmacotherapy of diabetic neuropathic pain. Drug Dev Res 76: 442-449, 2015.
AB - Preclinical Research The aim of this study was to evaluate fosinopril-induced changes in hemodynamic parameters and tactile allodynia in a rat model of diabetes. Diabetes was induced by streptozotocin (STZ; 50 mg/kg, i.p.) in male Wistar rats. STZ produced hyperglycemia, weight loss, polydipsia, polyphagia, and polyuria as well as long-term arterial hypotension, bradycardia, and tactile allodynia at 10-12 weeks. Daily administration of the angiotensin converting enzyme inhibitor, fosinopril (25 mg/kg, p.o., for 11 weeks) partially reduced the loss of body weight, decreased hyperglycemia, and systolic blood pressure in diabetic rats. Likewise, systemic administration of fosinopril prevented the development and maintenance of tactile allodynia in STZ-induced diabetic rats. These data suggest that fosinopril may have a role in the pharmacotherapy of diabetic neuropathic pain. Drug Dev Res 76: 442-449, 2015.
KW - allodynia
KW - diabetic neuropathy
KW - fosinopril
KW - streptozotocin
UR - http://www.scopus.com/inward/record.url?scp=84955160792&partnerID=8YFLogxK
U2 - 10.1002/ddr.21280
DO - 10.1002/ddr.21280
M3 - Artículo
SN - 0272-4391
VL - 76
SP - 442
EP - 449
JO - Drug Development Research
JF - Drug Development Research
IS - 8
ER -